132 related articles for article (PubMed ID: 23375537)
1. Clinical utility of different botulinum neurotoxin preparations.
Abrams SB; Hallett M
Toxicon; 2013 Jun; 67():81-6. PubMed ID: 23375537
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
[TBL] [Abstract][Full Text] [Related]
6. Overview of botulinum neurotoxins.
Lowe NJ
J Cosmet Laser Ther; 2007; 9 Suppl 1():11-6. PubMed ID: 17885881
[TBL] [Abstract][Full Text] [Related]
7. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Simpson DM; Gracies JM; Graham HK; Miyasaki JM; Naumann M; Russman B; Simpson LL; So Y;
Neurology; 2008 May; 70(19):1691-8. PubMed ID: 18458229
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence?
Moore AP
Eur J Neurol; 2002 May; 9 Suppl 1():42-7; dicussion 53-61. PubMed ID: 11918649
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A in children. New indication for limb spasticity.
Prescrire Int; 2011 Mar; 20(114):68. PubMed ID: 21648226
[No Abstract] [Full Text] [Related]
10. [Botulinum toxin in the head and neck region].
Laskawi R
HNO; 2012 Jun; 60(6):474. PubMed ID: 22669433
[No Abstract] [Full Text] [Related]
11. BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
Veverka T; Hluštík P; Tomášová Z; Hok P; Otruba P; Král M; Tüdös Z; Zapletalová J; Herzig R; Krobot A; Kaňovský P
J Neurol Sci; 2012 Aug; 319(1-2):89-95. PubMed ID: 22687958
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin for the management of adult patients with upper motor neuron syndrome.
Esquenazi A; Mayer NH; Elia AE; Albanese A
Toxicon; 2009 Oct; 54(5):634-8. PubMed ID: 19470335
[TBL] [Abstract][Full Text] [Related]
13. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Naumann M; So Y; Argoff CE; Childers MK; Dykstra DD; Gronseth GS; Jabbari B; Kaufmann HC; Schurch B; Silberstein SD; Simpson DM;
Neurology; 2008 May; 70(19):1707-14. PubMed ID: 18458231
[TBL] [Abstract][Full Text] [Related]
14. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).
Dobkin BH; Landau WM; Sahrmann S; Thomas Thach W; Simpson DM; Gracies JM; Graham K; Hallett M; Miyasaki J; Naumann M; Russman B; Simpson L; So Y
Neurology; 2009 Sep; 73(9):736; author reply 737-8. PubMed ID: 19720984
[No Abstract] [Full Text] [Related]
15. [Guidelines for the treatment of spasticity in adults using Botulinum toxin].
Aguilar-Barberá M; Bori-Fortuny I; García-Aymerich V; García-Ruiz Espiga PJ; Garreta-Figuera R; Herrera-Galante A; Lanzas-Melendo G; de Miguel-León I; Miquel-Rodríguez F; Pascual-Pascual SI; Póo P; Vivancos-Matellano F
Rev Neurol; 2004 May 16-31; 38(10):971-8. PubMed ID: 15175981
[TBL] [Abstract][Full Text] [Related]
16. [Use of botulinum neurotoxin for spasticity].
Mukai Y; Kaji R
Brain Nerve; 2008 Dec; 60(12):1421-6. PubMed ID: 19110753
[TBL] [Abstract][Full Text] [Related]
17. The evolution of botulinum neurotoxin type A for cosmetic applications.
Carruthers J; Carruthers A
J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
[TBL] [Abstract][Full Text] [Related]
18. Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice.
Wissel J; Ri S
Expert Rev Neurother; 2022 Jan; 22(1):27-42. PubMed ID: 34933648
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
Apostolidis A
Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
[TBL] [Abstract][Full Text] [Related]
20. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
